Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (241-250 of 442) with videos related to

Pageof 45
Sort By:
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lab on a Chip|October 17, 2013
Digital holography as a method for 3D imaging and estimating the biovolume of motile cellsF Merola, L Miccio, P Memmolo, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2026
Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysisBeth A Childs, Eslam A Elghonaimy, Praveen Ramakrishnan Geethakumari, et al.
The Journal of Dermatological Treatment|March 9, 2026
Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 yearsPaolo Gisondi, Boni Elewski, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Journal of Cardiovascular Pharmacology|August 11, 2023
Cardiovascular Risk Management in Patients Treated With Janus Kinase InhibitorsJill T Shah, Keya T Shah, Alisa N Femia, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 7, 2025
Cutaneous lupus matters: Independent and additive quality-of-life burden shown by 2022 WLFGI SurveyArianna J Zhang, Nnenna Ezeh, Beth Childs, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
Pageof 45

Showing results (241-250 of 442) with videos related to

Sort By:
Pageof 45
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lab on a Chip|October 17, 2013
Digital holography as a method for 3D imaging and estimating the biovolume of motile cellsF Merola, L Miccio, P Memmolo, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2026
Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysisBeth A Childs, Eslam A Elghonaimy, Praveen Ramakrishnan Geethakumari, et al.
The Journal of Dermatological Treatment|March 9, 2026
Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 yearsPaolo Gisondi, Boni Elewski, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Journal of Cardiovascular Pharmacology|August 11, 2023
Cardiovascular Risk Management in Patients Treated With Janus Kinase InhibitorsJill T Shah, Keya T Shah, Alisa N Femia, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 7, 2025
Cutaneous lupus matters: Independent and additive quality-of-life burden shown by 2022 WLFGI SurveyArianna J Zhang, Nnenna Ezeh, Beth Childs, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
Pageof 45